Product Description
Apixaban is used help prevent strokes or blood clots in people who have atrial fibrillation (a condition in which the heart beats irregularly, increasing the chance of clots forming in the body and possibly causing strokes) that is not caused by heart valve disease. Apixaban is also used to prevent deep vein thrombosis (DVT; a blood clot, usually in the leg) and pulmonary embolism (PE; a blood clot in the lung) in people who are having hip replacement or knee replacement surgery. Apixaban is also used to treat DVT and PE and may be continued to prevent DVT and PE from happening again after the initial treatment is completed. Apixaban is in a class of medications called factor Xa inhibitors. It works by blocking the action of a certain natural substance that helps blood clots to form. (Sourced from: https://medlineplus.gov/druginfo/meds/a613032.html)
Mechanisms of Action: VKOR Antagonist, FXa Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: Eastern America
Company CEO: Giovanni Caforio
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Finland, France, Germany, Greece, India, Indonesia, Israel, Italy, Korea, Malaysia, Mexico, Netherlands, Norway, Philippines, Poland, Russia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 14
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Atrial Fibrillation|Breast Cancer|Cerebral Hemorrhage|Colorectal Cancer|Myelofibrosis|Polycythemia Vera|Prostate Cancer|Stroke|Thrombocythemia, Essential|Thrombosis|Venous Thromboembolism
Phase 2: Edema|Healthy Volunteers|Heart Failure|Hypoalbuminemia|Kidney Diseases|Membranous Nephropathy|Nephrotic Syndrome|Proteinuria
Phase 1: Hypertension, Pulmonary
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12618001077257p |
2006-7041-83/hah | P1 |
Not yet recruiting |
Hypertension, Pulmonary |
2018-09-11 |
|||
2020-004652-15 |
AVAJAK | P3 |
Active, not recruiting |
Myelofibrosis|Polycythemia Vera|Thrombocythemia, Essential |
2026-06-03 |
|||
NCT03243175 |
A3ICH | P3 |
Recruiting |
Atrial Fibrillation|Cerebral Hemorrhage |
2026-01-01 |
2025-02-07 |
Primary Completion Date|Primary Endpoints|Start Date |
|
2017-003342-25 |
API-CAT | P3 |
Completed |
Breast Cancer|Prostate Cancer|Colorectal Cancer |
2024-10-24 |
2025-07-09 |
Treatments |
|
NCT03692065 |
API-CAT | P3 |
Completed |
Thrombosis |
2024-09-06 |
24% |
2025-02-07 |
Patient Enrollment|Primary Endpoints|Treatments |
2018-002176-41 |
2018-002176-41 | P3 |
Completed |
Atrial Fibrillation|Stroke |
2024-07-25 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
2017-002433-31 |
RENOVE | P3 |
Active, not recruiting |
Venous Thromboembolism |
2021-09-13 |
2022-03-13 |
Treatments |
|
NCT04865978 |
DOAC LVAD | P2 |
Completed |
Heart Failure |
2023-10-05 |
63% |
2023-12-09 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT07265466 |
JP-1366-106 | P1 |
Recruiting |
Healthy Volunteers |
2026-03-30 |
88% |
2025-12-05 |
Primary Endpoints |
NCT06043297 |
NCT06043297 | P1 |
Completed |
Healthy Volunteers |
2023-03-06 |
2023-09-22 |
Primary Endpoints|Treatments |
|
CTR20243572 |
CTR20243572 | P1 |
Recruiting |
Healthy Volunteers |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20132406 |
CTR20132406 | P3 |
Active, not recruiting |
Atrial Fibrillation |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
|
NCT06689436 |
TAH3311-CP-2301 | P2 |
Completed |
Healthy Volunteers |
2025-01-15 |
12% |
2025-04-12 |
Primary Completion Date|Primary Endpoints|Start Date|Treatments|Trial Status |
2019-001212-29 |
2019-001212-29 | P2 |
Active, not recruiting |
Proteinuria|Membranous Nephropathy|Nephrotic Syndrome|Kidney Diseases|Hypoalbuminemia|Edema |
None |
2022-03-13 |
Treatments |